NCT04174716 2026-04-17
VASTUS
Idience Co., Ltd.
Phase 1/2 Completed
Clinical Trials
12 trialsNCT04627740 2026-01-20
Anti-ALPP CAR-T Cells Immunotherapy for Advanced Solid Tumors
Xinqiao Hospital of Chongqing
Phase 1/2 Completed
NCT02240238 2025-01-22
Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer
NanoCarrier Co., Ltd.
Phase 1/2 Completed
NCT01283945 2024-07-25
Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors
Servier
Phase 1/2 Completed
NCT02598960 2023-03-06
An Investigational Immuno-therapy Study of Experimental Medication BMS-986156, Given by Itself or in Combination With Nivolumab in Patients With Solid Cancers or Cancers That Have Spread.
Bristol-Myers Squibb
Phase 1/2 Completed
NCT02593786 2022-10-24
CheckMate 077
Bristol-Myers Squibb
Phase 1/2 Completed
NCT03965845 2022-09-19
A Study of Telaglenastat (CB-839) in Combination With Palbociclib in Patients With Solid Tumors
Calithera Biosciences, Inc
Phase 1/2 Completed
NCT02639546 2022-09-16
iMATRIXcobi
Hoffmann-La Roche
Phase 1/2 Completed
NCT02303028 2022-06-28
TOPAZ
The Hospital for Sick Children
Phase 1/2 Completed
NCT03035591 2019-10-15
BETIDES
Orion Corporation, Orion Pharma
Phase 1/2 Completed
NCT01949688 2019-03-19
Safety and Efficacy Study of Epitope Peptide To Treat HLA-A*24 or A*02-positive Advanced Solid Tumors
Shiga University
Phase 1/2 Completed
NCT00703378 2012-03-28
Target Dosing of Docetaxel Through Pharmacokinetic/Pharmacodynamic Optimisation of the First Chemotherapeutic Cycle
National University Hospital, Singapore
Phase 1/2 Completed